Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia

Raal, Frederick J., Kallend, David, Ray, Kausik K., Turner, Traci, Koenig, Wolfgang, Wright, R. Scott, Wijngaard, Peter L.J., Curcio, Danielle, Jaros, Mark J., Leiter, Lawrence A., Kastelein, John J.P.·2020·New England Journal of Medicine
DOI 10.1056/nejmoa1913805

Cited by (820)

Items 601–700 of 820

  1. Small interfering RNA: potential in real-world clinical practice
    A. Sh. Motrinchuk, Alina R. Kasimova · 2024 · Real-World Data & Evidence
  2. Pharmacological methods to lower lipoprotein(a) levels
    Natalia Wierzbowska, Joanna Olejnik-Wojciechowska, Aleksandra Dąbrowska, Karolina Żurawska · 2024 · Medical Research Journal
  3. In vivo evaluation of germinated IR-64 brown rice dietary administration on the lipid blood profiles of rats with hypercholesterolemia
    Sisilia Anisa Mantiri, Yunika Mayangsari, Ardiansyah Ardiansyah, Hitoshi Shirakawa, Wahyu Dwi Saputra · 2024 · Nutrire
  4. Molecular Therapeutics in Development to Treat Hyperlipoproteinemia
    Maud Ahmad, Robert Alexander Hegele · 2025 · Molecular Diagnosis & Therapy
  5. 2024 consensus document of the Italian Society of Arterial Hypertension (SIIA) and the Italian Society of Cardiovascular Prevention (SIPREC): update on LDL cholesterol lowering in patients with arterial hypertension
    María Lorenza Muiesan, Agostino Virdis, Giuliano Tocci, Claudio Borghi, Arrigo F.G. Cicero, Claudio Ferri, Matteo Pirro, Alberto Corsini, Massimo Volpe · 2025 · High Blood Pressure & Cardiovascular Prevention
  6. A Multifaceted Review on Neodiosmin In Planta Distribution, (Bio)synthesis, Food and Health Effects
    Yuxuan Zhao, Jingyimei Liang, Xincheng Wu, Mohamed Ali Farag, Predrag Putnik · 2025 · Future Postharvest and Food
  7. The Creative Academic Leader: Six Attributes That Shape Discovery, Integrity, and Impact
    Mandeep R. Mehra, MILICA VUKIĆEVIĆ, Andreas Oliver Zuckermann · 2025 · Journal of Cardiac Failure
  8. Inclisiran and siRNA-Based Lipid Lowering: A New Frontier Including ANGPTL3 Inhibitors and Apo C III Inhibitors
    Ramya Pechetty, P. Seshagiri Rao, Tripti Deb, Chandana Shekar, K. Deepthi · 2025 · Indian Journal of Cardiovascular Disease in Women
  9. Approach to Resistant Hypertension from Cardiology and Nephrology Standpoints
    Luke Joseph Laffin, George L. Bakris · 2021 · Cardiology Clinics
  10. Emerging Cholesterol Modulators for Atherosclerotic Cardiovascular Disease
    Sangkyu Noh, Kevin Mai, Madeleine Shaver, Stanley Yong, MIRKO MOSTAGHIMI, Grace Oh, Mohamed M. Radwan · 2022 · The American Journal of the Medical Sciences
  11. Safety Issues Associated With the Clinical Application of PCSK9 Inhibitors: Current Findings
    Dan Wang, Daqing Zhang · 2022 · Cardiology in Review
  12. Clinical strategies for reducing cholesterol levels
    Claude K. Lardinois, Samantha Karr · 2022 · Elsevier eBooks
  13. Control of dyslipidemia in the prevention of recurrent ischemic cerebrovascular accidents (expert opinion)
    Marine Movsesovna Tanashyan, Nikolay A Shamalov, Igor A. Voznyuk, S. N. Yanishevsky, O. I. Vinogradov, Dina Rustemovna Khasanova, О. В. Тихомирова, Vladimir Anatolyevich Parfenov, E. V. Oshchepkova, M. V. Ezhov et al. · 2022 · Neurology neuropsychiatry Psychosomatics
  14. The Egyptian Association of Vascular Biology and Atherosclerosis (EAVA) Perspectives on the Usage of Inclisiran
    Ahmed Shawky, Ahmed Bendary, Atef Elbahry, El-Sayed Mohamed Farag, Tamer Mohamed Nasr Mostafa, Osama Sanad, Ahmed Elkersh, Mohammed Selim, Hany Ibrahim Ragy, Hazem Khamis et al. · 2022 · Cardiology and Therapy
  15. Synthesis of folate-labeled siRNAs from a folate derivative phosphoramidite
    Lidya Salim, Jean‐Paul Desaulniers · 2023 · Organic & Biomolecular Chemistry
  16. СУЧАСНА ГІПОЛІПІДЕМІЧНА ТЕРАПІЯ (ОГЛЯД ЛІТЕРАТУРИ)
    Yu. V. Botsiurko · 2022 · Прикарпатський вісник наукового товариства імені Шевченка ПУЛЬС
  17. Special Patient Populations
    Maya S. Safarova, Raul Dias Santos, Patrick M. Moriarty · 2023 · Elsevier eBooks
  18. Update on Inclisiran for Treatment of Hypercholesterolemia
    Nasser E. Mikhail · 2020 · Journal of Diabetes Research Review & Reports
  19. Working towards full eradication of lipid-driven cardiovascular risk?
    Nick S. Nurmohamed, Erik S.G. Stroes · 2021 · Netherlands Heart Journal
  20. Integrating Patient-Reported Outcomes Into Clinical Genetic Testing for Familial Hypercholesterolemia
    Rachele Hendricks‐Sturrup, Robert Block, Christine Y. Lu · 2021 · Journal of patient-centered research and reviews
  21. Inclisiran. A New Kid on the New Block for Treating Hypercholesterolaemia
    Vasilios Gabriel Athyros, Chrysoula Boutari, Konstantinos P. Imprialos, Michael N. Doumas · 2020 · Current Vascular Pharmacology
  22. A new PCSK-9 monoclonal antibody for lowering LDL-cholesterol and lipoprotein(a) in Chinese patients with familial hypercholesterolaemia
    Seyed Saeed Tamehri Zadeh, Dick C. Chan, Gerald Francis Watts · 2025 · Cardiovascular Research
  23. Modern possibilities of intensive treatment of dyslipidemia and gaps in its control: literature review
    Vera N. Larina, Головко Милада Геннадиевна, Ларин Владимир Геннадьевич, Tatyana N. Mironovna, D. A. Orlov · 2023 · Cardiosomatics
  24. Gene Therapy of Extracellular Vesicles in Cardiovascular and Metabolic Diseases
    Árpád Ferenc Kovács · 2023 · Advances in experimental medicine and biology
  25. Dyslipidaemia in elderly and stroke patients
    Dhiman Kahali · 2024 · Indian Heart Journal
  26. Adverse events associated with inclisiran: a real-world disproportionality analysis based on the FAERS database
    Xuyang Cai, Shaopeng Peng, Shangzhen Mu, Song Lei, Juan Li, Xiaoxue Tang, Feng Qiu · 2024 · Expert Opinion on Drug Safety
  27. Review of p.(Val429Met), a Variant of LDLR That Is Associated with Familial Hypercholesterolemia
    Eric Francis-Jerome Jotch, Mark S. Kindy · 2024 · Cardiogenetics
  28. Eficacia, beneficio y seguridad de inclisiran
    José López‐Miranda · 2024 · Clínica e Investigación en Arteriosclerosis
  29. Small Interfering RNAs (siRNAs)
    Tosar, Juan Pablo · 2024 · Topics in Medicinal Chemistry
  30. Association between inclisiran and the risk of arrhythmias
    Vikash Jaiswal, Fakhar Latif, Zarghoona Wajid, Nishat Shama, Anupam Halder, Dhrubajyoti Bandyopadhyay, Jishanth Mattumpuram, Monodeep Biswas · 2025 · IJC Heart & Vasculature
  31. Apparent Nonresponse to PCSK9 Inhibition in a Patient With Heterozygous Familial Hypercholesterolemia Due to PCSK9 Gene Duplication
    Mustansir Pindwarawala, S Bose, Liam R. Brunham · 2025 · JACC Case Reports
  32. Which is the optimal choice in lipid-lowering therapy for reducing major cardiovascular events? a network meta-analysis
    Qiang Niu, Qilei Wang, Feng Chen, Bo Li · 2025 · Frontiers in Pharmacology
  33. Inclisiran in a real-world single-center registry of patients with very high atherosclerotic cardiovascular risk
    Antonio Centola, Michelangelo Carbonara, Serena De Nuzzo, Andrea Cuculo, Antonio Ruggiero, Giulio Campanale, Massimo Iacoviello, Paola Gargiulo, Pasquale Perrone Filardi, Natale Daniele Brunetti · 2025 · Atherosclerosis Plus
  34. The Effects of Inclisiran on the Subclinical Prothrombotic and Platelet Activation Markers in Patients at High Cardiovascular Risk
    Mateusz Maligłówka, Adrianna Dec, Łukasz Bułdak, Bogusław Okopień · 2025 · Journal of Cardiovascular Development and Disease
  35. Ribonucleic acid and gene therapies in cardiovascular disease: clinical applications, delivery challenges and emerging precision tools
    Alex J Jordan, Craig Balmforth, Neil J. Craig, Neeraj Dhaun, Andrew Howard Baker, Marc Richard Dweck, David Ernest Newby · 2025 · Heart
  36. Imputation of untreated LDL-C in treated subjects with homozygous familial hypercholesterolaemia: An international collaboration
    G.B. John Mancini, Arnold Ryomoto, Isabelle L. Ruel, Iulia Iatan, Frederick Johan Raal, Raul D. Santos, Ana Paula Marte Chacra, Robert Alexander Hegele, Brooke A. Kennedy, Liam R. Brunham et al. · 2025 · Atherosclerosis
  37. Efficacy and safety of proprotein convertase subtilisin/kexin type 9 inhibitors for adults with familial hypercholesterolemia: A network meta-analysis
    Weiwei Ding, Lirui Sun, Yun Shi, Lei Tian · 2025 · International Journal of Cardiology Cardiovascular Risk and Prevention
  38. Inclisiran in Dyslipidemia with High Residual Platelet Reactivity
    D. A. Kapsultanova, Шолпан Болатовна Жангелова, Friba Nurmukhammad, Zulfiya Makasheva, Orazbek Sakhov, Galkina Tamara, Farida Rustamova, Dana Akhmentayeva, Botakoz Aubakirova · 2026 · Diseases
  39. Therapeutic delivery of albumin-binding siRNA targeting IRS2 to diverse cell types reduces mammary tumor growth
    Claire E. Tocheny, Julianna E. Buchwald, Christopher D Dahlke, Hassan H. Fakih, Jennifer S. Morgan, Ashley Summers, Christi A. Silva, Samuel O. Jackson, Ji-Sun Lee, Michael-Anthony Card et al. · 2026 · Molecular Therapy
  40. Therapeutic Effects of PCSK9 Inhibitors on Lp(a)-Associated Atherosclerosis: Evidence and Perspectives
    Xinyan Li, Zhongsu Wang, Juan Liang, Bingsong Li, Qingxin Meng, Mei Gao · 2026 · Journal of Cardiovascular Pharmacology
  41. Low-density lipoprotein cholesterol lowering and out-of-pocket cost of inclisiran therapy in the United States
    Nihar R. Desai, Nicholas Van Hise, Xiaoli Niu, Alan S. Brown · 2026 · Journal of clinical lipidology
  42. A review on RNA technologies renaissance: a paradigm shift shaping the future of modern medicine
    Suraj Pratap Singh, Poonam Mundlia, Akanksha Manmohan Sharma, Harjeet Kaur, Bhawna Chaubey, Akhil Khajuria, Mary Chatterjee, Pradeep Kumar Jaiswal, Pavitra Ranawat, Gurpal Singh et al. · 2026 · Next Bioengineering
  43. Upfront Combination or Stepwise Escalation: Personalising LDL-C Reduction in Clinical Practice
    Angela Pirillo, Alberico Luigi Catapano · 2026 · Current Atherosclerosis Reports
  44. RNA interference for lipid disorders: is this the future?
    Miguel Nassif, Renata TJ Fazoli, Giuliano Generoso · 2026 · Current Opinion in Lipidology
  45. Secondary prevention and cardiac rehabilitation in patients with chronic coronary syndromes: long-term management and treatment
    Aristi Boulmpou, Maria-Alexandra Pană, Çiğdem İleri, Irfan Ullah, Stefano Cacciatore, Luigi Spadafora, Marco Bernardi, Ștefan Busnatu, Giuseppe Biondi‐Zoccai, Francesco Perone · 2026 · Postgraduate Medical Journal
  46. Long-Acting RNA Interference Therapies for Cardiovascular Risk Reduction: Current Evidence and Emerging Targets
    Kahtan Fadah, Mohammed Alomari, Mohanad Elchouemi, Richard A. Lange · 2026 · Current Cardiology Reports
  47. Response to PCSK9 Inhibition Based on LDL Receptor Function in Familial Hypercholesterolemia
    Frederick Johan Raal, Nyda Fourie, Russell Scott, D J Blom, Matthys De Vries Basson, Meral Kayikcioglu, Mendel M. Roth, Jeffrey Vest, David G. Kallend, Evan A. Stein · 2026 · JAMA Cardiology
  48. Expert consensus on Lipoprotein(a) in the Gulf countries: Navigating cardiovascular risk and therapeutic advances
    Wael A. Almahmeed, Hani Mohamed Sabbour, Ronney S. Shantouf, Asma Khaled Aljaberi, Hassan El Tamimi, Farhana Bin Lootah, Nasreen Al Sayed, Juwairia Al Ali, Mousa A.J. Akbar, Abdullah Shehab et al. · 2026 · Atherosclerosis Plus
  49. Emergent RNA targets in cardiovascular disease: likely candidates for treatment development
    Veronica Barbi, Maria Anele Romeo, Michela Gottardi Zamperla, Federico Favretto, Sandra Atlante, Alessia Lucotti, Carlo Gaetano, Francesco Martelli · 2026 · Expert Opinion on Therapeutic Targets
  50. Beyond lipid lowering: targeting lncRNAs as a novel therapeutic strategy for vascular wall defense in atherosclerosis
    Tingting Chen, Yuxin Shang, Shanpeng Liu, Yuqing Pan, Chenxia Wu, Chenchen Meng, Tiantian Zheng, Wei Mao, Tingting Chen · 2026 · Pharmacological Research
  51. A versatile strategy for oligonucleotide functionalization via on-support phosphitylation
    Ayan Dasgupta, Sebastian Golojuch, Xiao Li, Nour Eddine Fahmi, Edward A. Anderson, Tom P Brown · 2026 · Nature Chemistry
  52. Lipoprotein apheresis: still needed in many patients, or soon a historical practice?
    Volker J. J. Schettler, Yamac Akgun, Jürgen Floege, Carmine Zoccali · 2026 · Clinical Kidney Journal
  53. Adenovirus vector-mediated delivery of the CRISPR-CasRx system enables gene knockdown with suppressed collateral activity
    Yuki OSAKADA, Sota Kidawara, Eiko Sakai, Akira Asayama, Fuminori Sakurai, Kahori Shimizu, Hiroyuki Mizuguchi · 2026 · Molecular Therapy — Nucleic Acids
  54. Modulation of noncoding RNAs (ncRNAs) and their potential role as therapeutics
    Luciano Pirola, Oskar Ciesielski, Marta Biesiekierska, Aneta Balcerczyk · 2021 · Elsevier eBooks
  55. Programmable Genome-Editing Technologies as Single-Course Therapeutics for Atherosclerotic Cardiovascular Disease
    Ishaan Jindal, Xiao Wang · 2022 · Current Atherosclerosis Reports
  56. 2022 Consensus Statement on the Management of Familial Hypercholesterolemia in Korea
    Chan Joo Lee, Minjae Yoon, Hyun‐Jae Kang, Byung Jin Kim, Sung Hee Choi, In‐Kyung Jeong, Sang‐Hak Lee, on behalf of Task Force Team for Familial Hypercholesterolemia, Korean Society of Lipid and Atherosclerosis · 2022 · Korean Journal of Medicine
  57. INCLISIRAN (LEQVIO): A FIRST-IN-CLASS SMALL INTERFERING RNA THERAPEUTIC DRUG APPROVED BY FDA FOR TREATING PRIMARY HYPERCHOLESTEROLEMIA OR DYSLIPIDEMIA
    PRIYANKA VENUNGOPAL, KARTHIKEYAN BALAKRISHNAN, Damal Kandadai Sriram, Melvin George · 2022 · Asian Journal of Pharmaceutical and Clinical Research
  58. Mesyl Phosphoramidate Oligonucleotides: A New Promising Type of Antisense Agents
    Dmitry A. Stetsenko · 2023 · Springer eBooks
  59. Inclisiran: new era of lipid-lowering therapy?
    Jan Beneš · 2023 · Cor et Vasa
  60. Lipids, atherosclerosis, and microvascular disease: Translating basic science into pharmacotherapeutics
    Bilal Bashir, Zohaib Iqbal, Jonathan D. Schofield, Handrean Soran · 2023 · Elsevier eBooks
  61. wind of change – PCSK9 inhibitors in hypolipidemic treatment. The Polish perspective
    Natalia Ilnicka, Patrycja Zuziak, Maria Sadlik, Daria Matyja, Leila Abod · 2023 · Journal of Education Health and Sport
  62. Clinicians' self-reported Efficacy in Cardiovascular Prevention Practice in the Southeastern United States
    Trevor Caldarera, Cynthia Ponir, Austin Lyles Seals, Megha Penmetsa, Edward H. Ip, Charles Amir German, Salim S. Virani, Animita Saha, Hayden Barry Bosworth, Justin B. Moore et al. · 2023 · Future Cardiology
  63. Aggressive course of atherosclerosis in hyperlipoproteinemia (a): a case series
    Намитоков Алим Муратович, В. К. Зафираки, Донец Екатерина Константиновна, O. V. Malyarevskaya, Карабахциева Карина Витальевна, A. N. Yahutl · 2023 · Rational Pharmacotherapy in Cardiology
  64. From Churchill to Elephants: The Role of Protective Genes against Cancer
    Annalisa Gazzellone, Eugenio Sangiorgi · 2024 · Genes
  65. Cholesterol, Atherosclerosis, Lipid-Lowering Therapy. Is It Completely Clear?
    A. P. Vasiliev, N. N. Streltsova · 2024 · Ural Medical Journal
  66. Pharmacotherapies for Cardiovascular Disease Prevention
    Jennifer Ballard‐Hernandez, Colleen Walsh Irwin · 2024 · Springer eBooks
  67. Pharmacological and clinical profile of inclisiran sodium, a long-acting LDL cholesterol lowering siRNA, LEQVIO for s.c. injection syringe 300 mg
    Tadayoshi Mikami, Yukari Fujiwara, Mizuki Akahori, Naoko Tomimatsu, Yuko Tamaki · 2024 · Folia Pharmacologica Japonica
  68. A Meta-analysis of the Regulation of Low-Density Lipoprotein Cholesterol and Proprotein Convertase Subtilisin-Kexin Type 9 with Inclisiran
    Yihan Li, Kefan Xue, Rui Hu, Xiao Hu, Ran Guo, Guo Hongxia, Gang Li · 2024 · American Journal of Cardiovascular Drugs
  69. Therapeutic Persistence in the Management of Familial Hypercholesterolemia
    Kevin H. Lin, Neil J. Stone · 2024 · JACC Case Reports
  70. Management of Hypercholesterolemia in Patients with Coronary Artery Disease: A Glimpse into the Future
    Alessandro Sciahbasi, Paola Russo, Michela Zuccanti, L Chiorazzo, F Castelli, Antonino Granatelli · 2024 · Journal of Clinical Medicine
  71. A comparative analysis of the safety profiles between inclisiran and other PCSK9 inhibitors from real-world evidence – what have we learned recently?
    Zhou Su, Zuyue Liao, Xiubi Chen, Jiong Tang, Yu Wang · 2024 · Expert Opinion on Drug Safety
  72. Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A meta-analysis of randomized controlled trials
    Zhang, Lei, Li, Yuan-Yuan, Liu, Xue-Hui, Liu, Hong-Jun, Xu, Qiang · 2025 · PLOS One
  73. Hypercholesterinämie - Wie erreiche ich ein LDL < 55 mg/dl?
    Anja Vogt · 2020 · MMW - Fortschritte der Medizin
  74. Phage display for targeting PCSK9
    Nicola Ferri · 2021 · EBioMedicine
  75. Biologic therapy for dyslipidemia
    David Karásek · 2021 · Vnitřní lékařství
  76. Impact of Covid-19 on asthmatic patients in Western region in Saudi Arabia
    Abdulrhman Nasser Zaher AlGhamdi, Amal Mohammed Albaqami, Areej Mohammed Abdullah, Doha Abdulrahmman Alsukhayri, Hamad Albulrahman Alawi, Ameera S. Baabbad · 2021 · World Family Medicine Journal/Middle East Journal of Family Medicine
  77. Inclisiran: Small Interfering Ribonucleic Acid Injectable for the Treatment of Hyperlipidemia
    Frances Hughes-Hubley, Mina Iskander, Angela Cheng-Lai, William H. Frishman, James J. Nawarskas · 2022 · Cardiology in Review
  78. RNA therapies for cardiovascular disease
    Ageliki Laina, Nikolaos I. Vlachogiannis, Kimon S. Stamatelopoulos, Konstantinos Stellos · 2022 · Elsevier eBooks
  79. No meaningful cardiovascular outcome data for inclisiran
    BMJ Publishing Group Ltd · 2023 · Drug and Therapeutics Bulletin
  80. Importance of identifying genetic cardiovarscular risk in pediatric patients
    Juan Manuel Sánchez-Vargas, Lina Johanna Moreno Giraldo · 2023 · Genetics and Clinical Genomics
  81. Future Energy Supply, Simulations with Limited Resources
    Léo Benichou · 2011 · KTH Publication Database DiVA (KTH Royal Institute of Technology)
  82. Sustained Relief of Chronic Pain via a Nav1.7-Targeting ASO–siRNA Conjugate
    Bin Ren, Chang Yu, Weiqin Yin, Zhuangchuan Yuan, Hongyu Chen, Yicao Liu, Bin Fang, Suyuan Liu, Lianchao Gao, Zhiwei Cao et al. · 2026 · bioRxiv (Cold Spring Harbor Laboratory)
  83. Effectiveness and Safety of Target-Specific RNA-Based Lipid-Lowering Therapies: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
    Widjaja, Jordan Steven, Adji, Arga Setyo, Baraja, Aufa, Dharmasaputra, Alan, Rosyadi, Ragil Nur, Komalasari, Intan, Mustofa, Ali, Multazam, Chaq El Chaq Zamzam, Alkaff, Firas Farisi, Saputra, Pandit Bagus Tri · 2026 · European Journal of Pharmacology
  84. Update Lipidologie
    Klaus Georg Parhofer · 2020 · Der Internist
  85. Universal cholesterol screening of youth—Are pediatric lipidologists smarter than a fifth grader?
    Brenda Kohn, Don P. Wilson · 2020 · Journal of clinical lipidology
  86. Pairwise genetic interactions modulate lipid plasma levels and cellular uptake
    M. Zimoń, Yunfeng Huang, Anthi Trasta, Jimmy Z. Liu, Chia‐Yen Chen, Aliaksandr A. Halavatyi, Peter Blattmann, Bernd Klaus, Christopher D. Whelan, David Sexton et al. · 2020 · bioRxiv (Cold Spring Harbor Laboratory)
  87. Perspektiven neuer lipidsenkender Substanzen für die Praxis
    Gerald Klose · 2020 · CardioVasc
  88. Neue lipidsenkende Substanzen
    David Sinning, Ulf Landmesser · 2021 · DMW - Deutsche Medizinische Wochenschrift
  89. Emerging New Lipid-Lowering Therapies in the Statin Era
    Albert Youngwoo Jang, Sang‐Ho Jo, Kwang Kon Koh · 2021 · CardioMetabolic Syndrome Journal
  90. Kardiologisches Risikofaktormanagement: Rauchen, Übergewicht, Bewegung, Diät, Dyslipidämie
    H. Lapp, S.T. Niepmann, M.U. Becher · 2021 · Elsevier eBooks
  91. PCSK9 Inhibiting siRNA
    R. Scott Wright · 2021 · Stroke revisited
  92. PCSK9 Inhibiting Monoclonal Antibodies
    Zain V. Ahmed, Prerak V. Juthani, Megan L. Lee, Nihar R. Desai · 2021 · Stroke revisited
  93. Elevated Lipoprotein (a) in Cardiac Outcomes: A Review
    Sahoo Alor, Strong Laura, Jensen Alexander, Flaherty Daniel, Anand Mukul, Alromheen Hassan, Singh, Sarabjeet · 2020 · Clinical Cardiology and Cardiovascular Interventions
  94. Are Statins the Optimal Therapy for Cardiovascular Risk in Patients with Diabetes? What Newer Agents Are There for the Treatment for Dyslipidemia in Diabetes? Are Triglycerides an Important Risk Factor for Diabetes?
    Recie Davern, Timothy O’Brien · 2021 · Wiley eBooks
  95. Risk factors and pharmacological therapy in patients with vascular disease
    Giuseppe Maiolino, Marco Rossato, Roberto Vettor · 2021 · Elsevier eBooks
  96. Genetic Disorders of Lipoprotein Metabolism: Diagnosis and Management
    Arjen J. Cupido, Robert M. Stoekenbroek, John J.P. Kastelein · 2020 · Springer eBooks
  97. Moderne Lipidsenker – ein Mittel gegen das Problem der Unterversorgung?
    Julius L. Katzmann, Ulrich Laufs · 2022 · Die Innere Medizin
  98. Inclisiran: Neue Option bei der Behandlung der familiären Hypercholesterinämie
    2020 · Zeitschrift für Gastroenterologie
  99. Inclisiran
    Etzel Gysling · 2021 · pharma-kritik
  100. Cholesterol: how to measure and how to treat
    Alison Pottle · 2022 · Practice Nursing